Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology...
Hence then, the article about fda clearance of investigational new drug application received for novel egfr her3 bispecific antibody drug conjugate avzo 1418 db 1418 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 )
Also on site :
- 30–35 terrorists on radar: Army steps up counterterror ops in J&K; intense vigil amid 'Chillai Kalan'
- Nine Years After Carrie Fisher Died, Billie Lourd Says Mom “Lives on Through Joy” With Kids, Dad Bryan Lourd
- No. 20 Virginia notches first 11-win season by beating 25th-ranked Missouri in the Gator Bowl